Study on Galunisertib and Enzalutamide for Treating Advanced Prostate Cancer

Inclusion Criteria

• Have advanced prostate cancer that continues to grow despite hormone therapy.
• Previously treated with the drug Abiraterone.
• Expected to live more than 3 months.
• Be in relatively good health, with a performance status score of 0 or 2.
• Be 18 years or older.
• Have cancer that can be measured by scans or tests.
• Agree to have a tumor biopsy if it is safe to do so.
• Be able to swallow pills.
• Have good organ and bone marrow function based on specific lab tests.
• Agree to use effective birth control during the study.
• Understand and agree to sign a consent form to participate.

Exclusion Criteria

• Have a history of cancer spreading to the brain.
• Have received chemotherapy for advanced prostate cancer.
• Had surgery within 4 weeks before starting the study treatment.
• Had radiation or other cancer treatments within 2 weeks before starting the study treatment.
• Used certain hormone therapies within 2 weeks before starting the study treatment.
• Used systemic steroids within 1 week before starting the study treatment.
• Previously treated with Enzalutamide, ARN-509, or Galeterone.
• Have moderate or severe heart disease.
• Have a history of seizures.
• Have uncontrolled health issues, such as active infections, heart failure, unstable chest pain, irregular heartbeats, or mental health conditions that could affect participation.
• Have a history of autoimmune diseases like inflammatory bowel disease, rheumatoid arthritis, or lupus.
• Have a known infection with HIV, hepatitis B, or hepatitis C.